Article | October 1, 2021

Writing and Enforcing GxP SOPs For Compliance

By Sarah Beale, MasterControl

iStock-1208998537-meeting-talking-business

Documentation is the thorn in the side of life sciences companies. The saying “if it isn’t documented, it didn’t happen” sums up the approach of the U.S. Food and Drug Administration (FDA) during inspections. A look at the data collected by the FDA makes it clear that in life sciences, standard operating procedures (SOPs) tend to be a problem. For fiscal year 2020, the most common inspectional observations for biologics, devices, and drugs involved SOPs.1

For biologics, companies failed to “establish, maintain, and follow manufacturing SOPs.” For devices, a “lack of or inadequate procedures,” specifically as they relate to corrective action/preventive action (CAPA). And with drugs, “procedures not in writing, fully followed,” specifically as they relate to the quality control unit. To avoid a Form 483, life sciences companies need a methodical approach to their SOPs.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: